Mode
Text Size
Log in / Sign up
N/A N=36

Single Center Pilot Study Using the ECGenius System to Collect Electrogram Data to Test an Ablation Impact Algorithm

Persistent Atrial Fibrillation · Cardiac Arrhythmia

Enrolled (actual)
36
Serious AEs
2.9%
Results posted
Dec 2025
Primary outcome: Primary: Ability to Collect CS Data — 34 Participants

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Cardiac Ablation for the treatment of persistent Atrial Fibrillation (Procedure)
Age
Adult, Older Adult · 21+ yrs
Sex
All
Sponsor
CathVision ApS
Primary completion
Oct 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Ability to Collect CS Data
34
SECONDARY
Measurement of AF Cycle Length
169.64

Summary

To acquire, amplify, digitize, and record atrial intracardiac electrophysiology signals during cardiac electrophysiology studies for the treatment of persistent atrial fibrillation and to use the recorded data to test the performance of an signal complexity visualization algorithm.

Eligibility Criteria

Inclusion Criteria

Eligible patients will meet all of the following inclusion criteria:

  • Patients scheduled for RF ablation indicated by the investigator for the treatment of persistent atrial fibrillation.
  • Male or female ≥ 21 years of age.
  • Able and willing to provide written informed consent prior to any clinical investigation related procedure.

Exclusion Criteria

Eligible patients will not meet any of the following exclusion criteria:

  • Current participation in another investigational drug or device study that interferes with this study.
  • Patients who, in the opinion of the investigator, are not candidates for this study.
  • Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the patient's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.
  • Life expectancy less than 12 month, in the opinion of the Investigator.
  • Patients who are considered part of any vulnerable population.
  • Patient is a prisoner.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05458648). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search